← Back to all trials
Available
NCT07216378
Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat
Conditions: Hereditary Angioedema
Sex: All
Ages: 2 Years – 11 Years
Sponsor: KalVista Pharmaceuticals, Ltd.
Location: KalVista Investigative Site San Diego California
Summary
The sebetralstat Early Access Program (EAP) provides early access to the investigational medicinal product (IMP) sebetralstat to eligible and approved Hereditary Angioedema (HAE) pediatric (ages 2-11) post-trial and naïve patients for the on-demand treatment of angioedema attacks where the treating Physician determines they might benefit from this treatment.
Eligibility Criteria
Inclusion Criteria:
* Male or female patients 2 to 11 years of age.
* Parent or LAR provides signed informed consent and patient provides assent (when applicable).
* Confirmed diagnosis of HAE.
Exclusion Criteria:
* Confirmed diagnosis of HAE with nC1-INH or acquired angioedema
* Patient weighs \
Source: ClinicalTrials.gov (NCT07216378). StuddyBuddy aggregates publicly available trial information.
